Zomedica Pharmaceuticals Corp Stock Total Debt
| ZOM Stock | USD 0.13 0.01 8.33% |
Zomedica Pharmaceuticals Corp fundamentals help investors to digest information that contributes to Zomedica Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Zomedica Stock. The fundamental analysis module provides a way to measure Zomedica Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Zomedica Pharmaceuticals stock.
As of the 24th of April 2024, Total Debt To Capitalization is likely to drop to 0.01. Zomedica | Total Debt |
Zomedica Pharmaceuticals Corp Company Total Debt Analysis
Zomedica Pharmaceuticals' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Zomedica Pharmaceuticals Total Debt | 2.73 M |
Most of Zomedica Pharmaceuticals' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Zomedica Pharmaceuticals Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Zomedica Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for Zomedica Pharmaceuticals is extremely important. It helps to project a fair market value of Zomedica Stock properly, considering its historical fundamentals such as Total Debt. Since Zomedica Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Zomedica Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Zomedica Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Zomedica Total Debt Historical Pattern
Today, most investors in Zomedica Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Zomedica Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Zomedica Pharmaceuticals total debt as a starting point in their analysis.
Zomedica Pharmaceuticals Total Debt |
| Timeline |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Zomedica Net Debt
Based on the latest financial disclosure, Zomedica Pharmaceuticals Corp has a Total Debt of 2.73 M. This is 99.9% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The total debt for all United States stocks is 99.95% higher than that of the company.
Zomedica Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Zomedica Pharmaceuticals' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Zomedica Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Zomedica Pharmaceuticals by comparing valuation metrics of similar companies.Zomedica Pharmaceuticals is currently under evaluation in total debt category among related companies.
Zomedica Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Zomedica Pharmaceuticals from analyzing Zomedica Pharmaceuticals' financial statements. These drivers represent accounts that assess Zomedica Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Zomedica Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 35.2M | 84.0M | 293.2M | 159.7M | 196.2M | 101.1M | |
| Enterprise Value | 34.7M | 23.9M | 99.6M | 134.1M | 186.0M | 195.3M |
Zomedica Fundamentals
| Return On Equity | -0.14 | ||||
| Return On Asset | -0.0741 | ||||
| Profit Margin | (1.37) % | ||||
| Operating Margin | (1.55) % | ||||
| Current Valuation | 39.72 M | ||||
| Shares Outstanding | 979.95 M | ||||
| Shares Owned By Insiders | 1.59 % | ||||
| Shares Owned By Institutions | 8.88 % | ||||
| Number Of Shares Shorted | 63.99 M | ||||
| Price To Book | 0.55 X | ||||
| Price To Sales | 5.25 X | ||||
| Revenue | 25.19 M | ||||
| Gross Profit | 13.65 M | ||||
| EBITDA | (25.29 M) | ||||
| Net Income | (34.53 M) | ||||
| Cash And Equivalents | 27.4 M | ||||
| Cash Per Share | 0.19 X | ||||
| Total Debt | 2.73 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 43.50 X | ||||
| Book Value Per Share | 0.24 X | ||||
| Cash Flow From Operations | (15.97 M) | ||||
| Short Ratio | 11.47 X | ||||
| Earnings Per Share | (0.03) X | ||||
| Target Price | 0.44 | ||||
| Number Of Employees | 144 | ||||
| Beta | 0.98 | ||||
| Market Capitalization | 127.49 M | ||||
| Total Asset | 253.2 M | ||||
| Retained Earnings | (170.93 M) | ||||
| Working Capital | 90.85 M | ||||
| Net Asset | 253.2 M |
About Zomedica Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Zomedica Pharmaceuticals Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Zomedica Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Zomedica Pharmaceuticals Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Zomedica Pharmaceuticals is a strong investment it is important to analyze Zomedica Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zomedica Pharmaceuticals' future performance. For an informed investment choice regarding Zomedica Stock, refer to the following important reports:Check out Zomedica Pharmaceuticals Piotroski F Score and Zomedica Pharmaceuticals Altman Z Score analysis. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Complementary Tools for Zomedica Stock analysis
When running Zomedica Pharmaceuticals' price analysis, check to measure Zomedica Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zomedica Pharmaceuticals is operating at the current time. Most of Zomedica Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Zomedica Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zomedica Pharmaceuticals' price. Additionally, you may evaluate how the addition of Zomedica Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |
Is Zomedica Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zomedica Pharmaceuticals. If investors know Zomedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zomedica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.03) | Revenue Per Share 0.026 | Quarterly Revenue Growth 0.192 | Return On Assets (0.07) | Return On Equity (0.14) |
The market value of Zomedica Pharmaceuticals is measured differently than its book value, which is the value of Zomedica that is recorded on the company's balance sheet. Investors also form their own opinion of Zomedica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zomedica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zomedica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zomedica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zomedica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zomedica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zomedica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.